Doug,
Can't say it makes much sense to me, but here is an extract from the 9/97 H&Q report:
"Given that peripheral arteries are much larger in diameter than arteries in the heart where most of the angioplasties are done, we are not expecting that any efficacy will be seen in this phase I study. However, we also expect that Lu-Tex angioplasty technique in this indication will demonstrate a clean safety profile, paving the way for efficacy studies to commence in both peripheral and cardiac arteries in 1998. With over 600,000 angioplasties performed annually in the US at an average cost of $25,000 per procedure, this is a huge potential market opportunity, but given its early stage of development, it can only be viewed as a wild card. "
BTW, some H&Q PCYC reports, including the one from which the above extract was taken, (but not the most recent update) is available at the Signal site:
recap.com
Peter |
